External validation of the ASTRAL score to predict 3-and 12-month functional outcome in the china national stroke registry
Autor
Liu, G.; Ntaios, G.; Zheng, H.; Wang, Y.; Michel, P.; Wang, D. Z.; Fang, J.; Papavasileiou, V.; Liu, L.; Dong, K.; Wang, C.; Zhao, X.Datum
2013Schlagwort
Zusammenfassung
BACKGROUND AND PURPOSE-: The ASTRAL score was recently introduced as a prognostic tool for acute ischemic stroke. It predicts 3-month outcome reliably in both the derivation and the validation European cohorts. We aimed to validate the ASTRAL score in a Chinese stroke population and moreover to explore its prognostic value to predict 12-month outcome. METHODS-: We applied the ASTRAL score to acute ischemic stroke patients admitted to 132 study sites of the China National Stroke Registry. Unfavorable outcome was assessed as a modified Rankin Scale score >2 at 3 and 12 months. Areas under the curve were calculated to quantify the prognostic value. Calibration was assessed by comparing predicted and observed probability of unfavorable outcome using Pearson correlation coefficient. RESULTS-: Among 3755 patients, 1473 (39.7%) had 3-month unfavorable outcome. Areas under the curve for 3 and 12 months were 0.82 and 0.81, respectively. There was high correlation between observed and expected probability of unfavorable 3-and 12-month outcome (Pearson correlation coefficient: 0.964 and 0.963, respectively). CONCLUSIONS-: ASTRAL score is a reliable tool to predict unfavorable outcome at 3 and 12 months after acute ischemic stroke in the Chinese population. It is a useful tool that can be readily applied in clinical practice to risk-stratify acute stroke patients. © 2013 American Heart Association, Inc.
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., Bhatia C., Garrett D., Cotte C., Isaacs S., Gugerty E., Davidson A., Marder G.S., Schnitzer A., Goldberg B., McGinn T., Davidson K.W., Barish M.A., Qiu M., Zhang M., Goldin M., Matsagkas M., Arnaoutoglou E., Spyropoulos A.C. (2021)Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether ... -
Small-vessel occlusion versus large-artery atherosclerotic strokes in diabetics: Patient characteristics, outcomes, and predictors of stroke mechanism
Ntaios G., Milionis H., Vemmos K., Makaritsis K., Ferrari J., Strbian D., Curtze S., Tatlisumak T., Michel P., Papavasileiou V. (2016)Introduction: Diabetes mellitus exerts a detrimental effect on cerebral vasculature affecting both macrovasculature and microvasculature. However, although ischaemic stroke is typically included among macrovascular diabetic ... -
The Global Registry for Hereditary Angioedema due to C1-Inhibitor Deficiency
Zanichelli A., Farkas H., Bouillet L., Bara N., Germenis A.E., Psarros F., Varga L., Andrási N., Boccon-Gibod I., Castiglioni Roffia M., Rutkowski M., Cancian M. (2021)Hereditary angioedema (HAE) is a rare condition, mostly due to genetic deficiency of complement C1 inhibitor (C1-INH). The rarity of HAE impedes extensive data collection and assessment of the impact of certain factors ...